AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Rhea-AI Summary

AbbVie (NYSE: ABBV) will invest $1.4 billion to build a new 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, supporting production of immunology, neuroscience and oncology medicines.

Construction begins in 2026 with completion expected by end of 2028, creating 734 full-time jobs and more than 2,000 construction jobs, and forming part of AbbVie's $100 billion U.S. R&D and capital commitment.

Positive

• $1.4 billion capital investment in a single campus
• Creation of 734 permanent jobs
• Generates > 2,000 construction jobs during development
• Part of a $100 billion U.S. R&D and capital commitment
• Designated U.S. center of excellence for SVP manufacturing

Negative

• None.

News Market Reaction – ABBV

-2.25%

-2.25% Session close to close

In the Apr 22 session, ABBV declined 2.25%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines a major U.S. expansion, with AbbVie committing $1.4 billion to a 185-acre...

Analysis

This announcement outlines a major U.S. expansion, with AbbVie committing $1.4 billion to a 185-acre Durham manufacturing campus as part of a broader $100 billion U.S. R&D and capital plan. The site is expected to create 734 long-term jobs and over 2,000 construction roles, and become a center of excellence for small volume parenterals. Investors may track construction progress toward the 2028 completion target and how this capacity supports immunology, neuroscience, and oncology growth.

Key Figures

Campus investment: $1.4 billion U.S. investment plan: $100 billion Campus size: 185 acres +5 more

8 metrics

Campus investment $1.4 billion New Durham, North Carolina manufacturing campus

U.S. investment plan $100 billion Planned U.S. R&D and capital investments over the next decade

Campus size 185 acres Durham manufacturing campus footprint

New jobs on campus 734 jobs Planned hires over the next four years at Durham site

Construction jobs 2,000+ jobs Estimated construction roles during campus development

Completion target End of 2028 Expected completion of Durham campus construction

U.S. employees 29,000 people Approximate AbbVie U.S. workforce across all states and Puerto Rico

Recent U.S. manufacturing spend $2.2 billion+ Committed to U.S. manufacturing over past 12 months

Historical Context

5 past events · Latest: Apr 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 14	Aesthetics partnership	Positive	+1.8%	Social-media partnership to promote Natrelle breast augmentation and patient education.
Apr 13	License agreement	Positive	-0.7%	Exclusive global license deal for pain compounds with milestones and royalties.
Apr 08	Grant program	Positive	+2.5%	BOTOX Cosmetic’s Confidence Collective grants and support for women entrepreneurs.
Apr 07	Training center	Positive	-0.1%	Opening of third U.S. Allergan Medical Institute training center in Austin.
Mar 31	Consumer promotion	Positive	+2.0%	CoolMonth CoolSculpting promotion with discounts and social giveaways for Allē members.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent AbbVie news has often seen positive reactions, with 3 aligned positive moves and 2 mild divergences on generally constructive announcements.

Recent Company History

Over recent months, AbbVie’s news flow has centered on aesthetics and strategic collaborations. Promotions like CoolMonth with $400 discounts and grant programs such as The Confidence Collective, which has awarded $1.2M since 2023, supported consumer-facing brands. Licensing activity, including a pain-focused deal with up to $715M in milestones, expanded the pipeline. Several of these updates produced positive single-day moves, suggesting investors have often rewarded brand and partnership news, which frames today’s large U.S. manufacturing investment.

Key Terms

small volume parenterals, parenteral, artificial intelligence (AI)

3 terms

small volume parenterals medical

"The first phase of construction will include small volume parenteral (SVP) drug product..."

Small volume parenterals are sterile liquid medicines packaged in single-dose vials, ampoules, prefilled syringes, or small infusion bags that are injected or infused into the body in relatively small amounts, bypassing the digestive system—think of vaccine or antibiotic shots and small IV doses. Investors watch them because making and distributing these products demands specialized sterile facilities, strict regulatory approval, and dependable supply chains, so production capacity, quality issues, or shortages can drive steady sales, pricing power, or sudden business risk for manufacturers.

parenteral medical

"Small volume parenterals are sterile injectable pharmaceutical products with volumes..."

Parenteral describes delivering a drug or medical product by injection or infusion so it bypasses the mouth and digestive system — for example, through a vein, muscle, or under the skin. For investors, parenteral products often mean different manufacturing standards, packaging, cold‑chain logistics, regulatory hurdles and higher margins compared with oral pills, much like shipping fragile goods requires different infrastructure than mailing a book.

artificial intelligence (AI) technical

"campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI)..."

Artificial intelligence (AI) is the development of computer systems that can perform tasks typically requiring human intelligence, such as understanding language, recognizing patterns, and making decisions. For investors, AI can enhance how businesses analyze data, automate processes, and innovate, potentially leading to increased efficiency and new opportunities in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Marks AbbVie's largest-ever capital investment in a single campus since its inception
• Investment demonstrates continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade
• New 185-acre campus will create 734 jobs to support production of AbbVie's immunology, neuroscience and oncology medicines
• Construction begins in 2026, with completion expected by the end of 2028

NORTH CHICAGO, Ill., April 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The state-of-the-art campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie's immunology, neuroscience and oncology medicines.

This is AbbVie's first major investment in North Carolina. The AbbVie Durham campus, located near Research Triangle Park, was selected for the strength of the region's local workforce and its ability to support future expansion. Construction will begin this year, with completion expected by the end of 2028.

"Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States," said Robert A. Michael, chairman and chief executive officer, AbbVie. "By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina."

Over the next four years, AbbVie plans to hire 734 people, including engineers, scientists, manufacturing operators and laboratory technicians. The project will also support the local economy by generating more than 2,000 construction jobs during campus development.

This project is part of the Company's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade. The first phase of construction will include small volume parenteral (SVP) drug product manufacturing facilities, next-generation laboratories, a warehouse, administrative offices and employee wellness facilities with room to support AbbVie's growing pipeline.

Small volume parenterals are sterile injectable pharmaceutical products with volumes typically less than 100 mL, including vials, prefilled cartridges and prefilled syringes containing medicines for injection or infusion. When completed, this campus will serve as AbbVie's U.S. center of excellence for SVP manufacturing and deliver next-generation medicines to patients in the U.S. and worldwide.

"We welcome AbbVie's major investment to North Carolina," said Governor Josh Stein. "When you combine our world-renowned research and innovation with a strong, thriving life sciences hub, North Carolina quickly becomes the premier location for biopharmaceutical companies to do business."

With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., including more than 6,000 at its U.S. manufacturing campuses. With this announcement, AbbVie has committed to investing more than $2.2 billion in U.S. manufacturing over the past 12 months and creating more than 1,300 jobs in North Carolina, Illinois, Arizona and Massachusetts.

About AbbVie 

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements  

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Media: Gabby Tarbert   (224) 244-0111 gabrielle.tarbert@abbvie.com

Investors: Liz Shea (847) 935-2211 liz.shea@abbvie.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html

SOURCE AbbVie

FAQ

What is AbbVie announcing for Durham, North Carolina (ABBV) on April 22, 2026?

AbbVie is investing $1.4 billion to build a 185-acre manufacturing campus in Durham. According to AbbVie, construction starts in 2026 with completion expected by the end of 2028 and aims to support SVP manufacturing for multiple therapy areas.

How many jobs will the AbbVie Durham campus (ABBV) create and when will hiring occur?

The project will hire 734 people over the next four years for engineering, manufacturing and lab roles. According to AbbVie, recruitment begins as construction progresses from 2026 toward the targeted 2028 completion.

What manufacturing capabilities will AbbVie's (ABBV) new Durham campus include?

The campus will include small volume parenteral (SVP) drug product manufacturing, next-generation labs, warehousing and offices. According to AbbVie, facilities are designed for sterile injectable products and to support immunology, neuroscience and oncology medicines.

How does the Durham investment fit AbbVie's broader U.S. strategy (ABBV)?

The $1.4 billion project is part of AbbVie's $100 billion commitment to U.S. R&D and capital investments over the next decade. According to AbbVie, the campus expands its domestic manufacturing footprint and supports pipeline production capacity.

When will construction start and when is the AbbVie Durham campus (ABBV) expected to open?

Construction will begin in 2026 and the campus is expected to be complete by the end of 2028. According to AbbVie, the first phase includes SVP manufacturing, laboratories, warehouse and employee facilities with room for expansion.